org$/$diweb$/$catalog$/$launch$/$package$/4/$sid$/169701890$

$2022$ ONCC Chemotherapy Immunotherapy Certificate Course R$...$

Question $5$ of $25$

Pembrolizumab is an immunotherapy agent that targets PD$-$L$1$ expression positivity greater than or equal to:

A$.40\%$

B$.50\%$

C$.60\%$

D$.75\%$